Cooper Financial Group Vertex Pharmaceuticals Inc Transaction History

Cooper Financial Group

$752 Million
Q3 2024

A detailed history of Cooper Financial Group transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Cooper Financial Group holds 4,031 shares of VRTX stock, worth $1.82 Million. This represents 0.25% of its overall portfolio holdings.

Number of Shares

4,031

Previous 3,747 7.58%

Holding current value

$1.82 Million

Previous $1.76 Million 6.72%

% of portfolio

0.25%

Previous 0.26%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$460.0 - $505.78 $130,640 - $143,641	284 Added 7.58%	4,031 $1.87 Million
Q2 2024 Jul 15, 2024	BUY	$392.81 - $485.53 $47,137 - $58,263	120 Added 3.31%	3,747 $1.76 Million
Q1 2024 Apr 11, 2024	BUY	$407.69 - $446.08 $163,076 - $178,432	400 Added 12.4%	3,627 $1.52 Million
Q4 2023 Jan 16, 2024	BUY	$343.0 - $410.68 $71,001 - $85,010	207 Added 6.85%	3,227 $1.31 Million
Q3 2023 Oct 13, 2023	BUY	$338.18 - $362.46 $9,807 - $10,511	29 Added 0.97%	3,020 $1.05 Million
Q2 2023 Jul 07, 2023	BUY	$314.42 - $351.91 $93,382 - $104,517	297 Added 11.02%	2,991 $1.05 Million
Q1 2023 May 10, 2023	BUY	$283.23 - $323.1 $65,142 - $74,313	230 Added 9.33%	2,694 $848,000
Q4 2022 Jan 13, 2023	BUY	$285.76 - $321.48 $133,164 - $149,809	466 Added 23.32%	2,464 $0
Q3 2022 Oct 13, 2022	BUY	$273.83 - $305.53 $251,102 - $280,171	917 Added 84.83%	1,998 $579,000
Q2 2022 Jul 11, 2022	BUY	$234.96 - $292.55 $28,665 - $35,691	122 Added 12.72%	1,081 $305,000
Q1 2022 Apr 12, 2022	BUY	$221.42 - $260.97 $4,871 - $5,741	22 Added 2.35%	959 $250,000
Q4 2021 Feb 11, 2022	BUY	$177.01 - $223.45 $165,858 - $209,372	937 New	937 $206,000

Others Institutions Holding VRTX

# of Institutions

1,723

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cooper Financial Group, based on Form 13F filings with the SEC.

News

Stay updated on Cooper Financial Group with notifications on news.

Account

Cooper Financial Group Vertex Pharmaceuticals Inc Transaction History